Sol-Gel Technologies Ltd 6-K, filed Mar 20, 2020
Sol-Gel Technologies Ltd. (SLGL)
6-K
2020-03-20
For: 2020-03-19
View Original
Added on
April 08, 2026
About this 6-K
Sol-Gel Technologies Ltd filed this 6-K on March 20, 2020.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the month of March 2020
Commission File Number 001-38367
SOL-GEL TECHNOLOGIES LTD.
(Translation of registrant’s name into English)
7 Golda Meir Street
Ness Ziona 7403650, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On March 19, 2020, the Company issued a press release announcing that it will report full year 2019 financial
results and corporate update, a copy of which press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Attached hereto and incorporated by reference herein is the following exhibit:
Exhibit 99.1: Registrant’s press release entitled: “Sol-Gel Technologies to Report Full Year
2019 Financial Results and Corporate Update”.
This Form 6-K and related exhibits are hereby incorporated by reference into the Company's Registration Statement on Form S-8 (Registration No. 333-223915) and its Registration Statement on Form F-3 (Registration No.
333-230564).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
SOL-GEL TECHNOLOGIES LTD.
|
||
|
|
|
|
|
|
Date: March 19, 2020
|
By:
|
/s. Gilad Mamlok
|
|
|
|
|
Gilad Mamlok
|
|
|
|
|
Chief Financial Officer
|
|
Exhibit 99.1
Sol-Gel Technologies to Report Full Year 2019
Financial Results and Corporate Update
Financial Results and Corporate Update
NESS ZIONA, Israel, March 19, 2020 (GLOBE NEWSWIRE) – Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing
branded and generic topical drug products for the treatment of skin diseases, today announced the Company will report full year 2019 financial results and provide a corporate update on Tuesday, March 24th 2020, 4:05 PM ET.
About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary
microencapsulation technology platform for Twyneo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor
inhibitor, erlotinib, for the treatment of punctate palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.
For further information, please contact:
Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433
Investor Contact:
Chiara Russo
Solebury Trout
+1-617-221-9197
crusso@soleburytrout.com
Source: Sol-Gel Technologies Ltd.